Patents Assigned to Biogen MA Inc.
  • Publication number: 20220213208
    Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: July 7, 2022
    Applicant: Biogen MA Inc.
    Inventors: Susan L. Kalled, Yen-Ming Hsu
  • Publication number: 20220213431
    Abstract: The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.
    Type: Application
    Filed: August 13, 2021
    Publication date: July 7, 2022
    Applicants: Biogen MA Inc., Samsung Bioepis
    Inventors: William C. Yang, Yao-Ming Huang, Marty Sinacore, Thomas Ryll, Jiuyi Lu, Jaesun Lee, Kyngju Lee, Hyoung Taek Lim, Eunchong Yang
  • Patent number: 11333670
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 17, 2022
    Assignee: Biogen MA Inc.
    Inventor: Theodore A. Yednock
  • Patent number: 11318120
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of making and using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: May 3, 2022
    Assignee: Biogen MA Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Patent number: 11318207
    Abstract: The present invention relates to a method for PEGylating interferon beta.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 3, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Robert S. Gronke, Orlando A. Jaquez
  • Publication number: 20220112216
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Application
    Filed: October 22, 2021
    Publication date: April 14, 2022
    Applicants: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • Patent number: 11291642
    Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 5, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
  • Patent number: 11292826
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 5, 2022
    Assignee: Biogen MA Inc.
    Inventors: Hq Han, Xiaolan Zhou
  • Patent number: 11292845
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: April 5, 2022
    Assignee: Biogen MA Inc.
    Inventor: Ivan Lieberburg
  • Patent number: 11287423
    Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 29, 2022
    Assignee: Biogen MA Inc.
    Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
  • Publication number: 20220089745
    Abstract: Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as dotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.
    Type: Application
    Filed: June 21, 2021
    Publication date: March 24, 2022
    Applicant: Biogen MA Inc.
    Inventors: Bradley Pearse, Joe Salas, Robert Peters, Christilyn Graff
  • Patent number: 11280794
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 22, 2022
    Assignee: Biogen MA Inc.
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
  • Patent number: 11280793
    Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 22, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Tatiana Plavina, Paula S. Hochman, Michaela Lerner
  • Publication number: 20220072117
    Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Biogen MA Inc.
    Inventor: Vissia Viglietta
  • Patent number: 11268119
    Abstract: The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 8, 2022
    Assignee: Biogen MA Inc.
    Inventors: Fernie Mitchelson, Erik Heller Hughes, Jessica Mondia, Robin Parish Hyde-Deruyscher
  • Publication number: 20220049301
    Abstract: The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with ?v?6 integrin inhibition or therapy with TGF-? pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against ?v?6-integrin and/or TGF-? pathway inhibitors.
    Type: Application
    Filed: March 2, 2021
    Publication date: February 17, 2022
    Applicants: Biogen MA Inc., The Regents of the University of California
    Inventors: Shelia M. Violette, Dean Sheppard
  • Patent number: 11249026
    Abstract: In one aspect, the disclosure provides a method of defining a Raman signature of a culture component, the method comprising: obtaining a Raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the Raman spectrum that are associated with the culture component, obtaining a Raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the Raman spectrum of the culture medium that are distorted compared to the peaks identified in the Raman spectrum of the culture component in a non-interfering or minimally-interfering solution.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Justin Moretto, Brandon Berry, Alex Doane
  • Patent number: 11246850
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 11248051
    Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 15, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Julie Taylor, Theodore A. Yednock
  • Publication number: 20210401981
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Application
    Filed: July 2, 2021
    Publication date: December 30, 2021
    Applicant: BIOGEN MA INC.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan